Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06751992

Neurocognitive Function Changes With Extended-Release Tacrolimus Among Older Kidney Transplant Recipients

The objective of this randomized controlled study is to assess the neurocognitive outcomes between individuals using immediate-release (IR) tacrolimus (Prograf®) and those who were converted to extended-release tacrolimus (Envarsus XR) among older kidney transplant recipients (KTRs).

Recruiting

Interested in participating?

Request Info

Key information

Age range

65 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

MGH Kidney Transplant Clinic

Boston, Massachusetts, 02114, United States

Location status: Recruiting

Location contact

Riella, M.D., Ph.D.

CONTACT

[email protected]

877-644-2860

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Able to give informed consent for participation in the study
  • Patients who have regular outpatient follow-up at the Massachusetts General Hospital (MGH) transplant center
  • ≥1 year since the latest kidney transplantation
  • On IR tacrolimus as maintenance therapy
  • At a stable therapeutic tacrolimus level (5-10 ng/ml) over the last ≥3 months
  • Stable kidney function [<20% variability between the last two estimated glomerular filtration rate (eGFR)]
  • Utilizing English or Spanish as the primary language

Exclusion criteria

  • Dual organ transplantation
  • Rejection within the last three months
  • History of moderate to severe dementia (defined by Dementia Severity Rating Scale ≥19)
  • History of Parkinson's disease
  • Decompensated liver disease
  • Active cancer
  • Uncontrolled depression or anxiety
  • Blindness
  • Deafness
  • Intellectual disabilities
  • Pregnancy
  • eGFR <15 mL/min/1.73 m2 at the time of enrollment
  • Total bilirubin >3.0 mg/dL

Treatment and study plan

Conversion to extended-release tacrolimus

Drug

Conversion from immediate-release tacrolimus (Prograf) to extended-release tacrolimus (Envarsus XR) as a part of the maintenance immunosuppressive treatment

Other names: Envarsus XR

Maintenance of immediate-release tacrolimus

Drug

Continuing immediate-release tacrolimus (Prograf) as a part of the maintenance immunosuppressive treatment

Other names: Prograf

Primary outcomes

  1. The difference in changes of neurocognitive function in intermediate-term (Total cognition composite, standard score)

    Time frame: 12 month

    Neurocognitive functions will be assessed across multiple cognitive domains using the NIH toolbox-Cognitive battery (NIHTB-CB) version 3. The NIHTB-CB version 3 encompasses seven tests to assess attention, executive function, language, memory, and processing speed. The total cognition composite will be derived by averaging normalized scores. The results will be reported in Standard Scores [SS; mean of 100, standard deviation (SD) of 15] adjusting the age of the subject. The investigators will compare the changes in standard score from baseline between the two intervention groups.

  2. The difference in changes of neurocognitive function in intermediate-term (Fluid composite, standard score)

    Time frame: 12 month

    The fluid composite score will be obtained using the NIH toolbox-Cognitive battery (NIHTB-CB) version 3, similarly as described above. The fluid cognition composite will be derived by averaging normalized scores. The results will be reported in Standard Scores [SS; mean of 100, standard deviation (SD) of 15] adjusting the age of the subject. The investigators will compare the changes in standard score from baseline between the two intervention groups.

  3. The difference in changes of neurocognitive function in intermediate-term (Crystallized composite, standard score)

    Time frame: 12 month

    The crystallized composite score will be obtained using the NIH toolbox-Cognitive battery (NIHTB-CB) version 3, similarly as described above. The crystallized cognition composite will be derived by averaging normalized scores. The results will be reported in Standard Scores [SS; mean of 100, standard deviation (SD) of 15] adjusting the age of the subject. The investigators will compare the changes in standard score from baseline between the two intervention groups.

  4. The difference in changes of neurocognitive function in intermediate-term (Total cognition composite, T score)

    Time frame: 12 month

    The total composite score will be obtained using the NIH toolbox-Cognitive battery (NIHTB-CB) version 3, similarly as described above. The total cognition composite will be derived by averaging normalized scores. The results will be reported in T scores (mean of 50 and SD of 10) with adjustments for age, gender, education, and race/ethnicity. The investigators will compare the changes in T score from baseline between the two intervention groups.

  5. The difference in changes of neurocognitive function in intermediate-term (Fluid composite, T score)

    Time frame: 12 month

    The fluid composite score will be obtained using the NIH toolbox-Cognitive battery (NIHTB-CB) version 3, similarly as described above. The fluid cognition composite will be derived by averaging normalized scores. The results will be reported in T scores (mean of 50 and SD of 10) with adjustments for age, gender, education, and race/ethnicity. The investigators will compare the changes in T score from baseline between the two intervention groups.

  6. The difference in changes of neurocognitive function in intermediate-term (Crystallized composite, T score)

    Time frame: 12 month

    The crystallized composite score will be obtained using the NIH toolbox-Cognitive battery (NIHTB-CB) version 3, similarly as described above. The crystallized cognition composite will be derived by averaging normalized scores. The results will be reported in T scores (mean of 50 and SD of 10) with adjustments for age, gender, education, and race/ethnicity. The investigators will compare the changes in T score from baseline between the two intervention groups.

Secondary outcomes

  1. The difference in changes of neurocognitive function in short-term (Total cognition composite, standard score)

    Time frame: 3 month

    Same as described above

  2. The difference in changes of neurocognitive function in short-term (Fluid composite, standard score)

    Time frame: 3 month

    Same as described above

  3. The difference in changes of neurocognitive function in short-term (Crystallized composite, standard score)

    Time frame: 3 month

    Same as described above

  4. The difference in changes of neurocognitive function in short-term (Total cognition composite, T score)

    Time frame: 3 month

    Same as described above

  5. The difference in changes of neurocognitive function in short-term (Fluid composite, T score)

    Time frame: 3 month

    Same as described above

  6. The difference in changes of neurocognitive function in short-term (Crystallized composite, T score)

    Time frame: 3 month

    Same as described above

  7. The changes in quality of life, measured by SONG-LP questionnaire

    Time frame: 3 month and 12 month

    The Standardized Outcome in Nephrology-Life Participation (SONG-LP) questionnaire will evaluate each participant's engagement in significant life domains in correlation with the intervention. This questionnaire assesses life participation in the areas of leisure, family, work, and social activities through four simple questions. The score ranges from 4 to 20, with a higher score indicating greater engagement in life activities. The difference in changes of total score from baseline between the two intervention groups will be obtained.

  8. The changes in tremor, measured by QUEST questionnaire

    Time frame: 3 month and 12 month

    Quality of Life in Essential Tremor (QUEST) questionnaire will be used to assess tremors subjectively. This questionnaire comprises 30 items contributing to the five dimensions: physical/activities of daily living, psychosocial, communication, hobbies/leisure, and work/finances. The investigators will also obtain self-rated tremor severity in various body parts. The score ranges from 0 to 120, with a higher score indicating a greater impact on their QOL from tremor. The investigators will compare the changes in total score and the score on each scale from baseline between the two intervention groups.

  9. The changes in sleep quantity, measured by a wearable device

    Time frame: 3 month and 12 month

    The investigators will assess each participant's sleep quantity using wearable devices. The participants will be instructed to wear the device continuously for 14 days at pre-specified time points during the study period. Sleep quantity will be represented by the total amount of time spent asleep. The difference in changes in sleep quantity from baseline will be compared between the two intervention groups.

  10. The changes in sleep quality, measured by a wearable device

    Time frame: 3 month and 12 month

    The investigators will objectively assess each participant's sleep quality using wearable devices. The participants will be instructed to wear the device continuously for 14 days at pre-specified time points during the study period. Sleep quality will be measured as a percentage of time spent in deep sleep and REM sleep to the total sleep time. A higher percentage indicates a better sleep quality. The changes in sleep quality from baseline will be compared between the two intervention groups.

Other outcomes

  1. Subgroup analysis of primary and secondary outcomes based on age group

    Time frame: At 3 month and 12 month

    The investigators will analyze the differential impact of the intervention in participants aged 75 years and older, compared to those under 75 years old.

  2. Subgroup analysis of primary and secondary outcomes based on gender

    Time frame: At 3 month and 12 month

    The investigators will perform a subgroup analysis for each outcome based on gender to determine whether the treatment effect varies between males and females.

  3. Subgroup analysis of primary and secondary outcomes based on education level

    Time frame: At 3 month and 12 month

    The investigators will analyze the differential impact of the intervention in participants with Bachelor's degree holders, compared to those without Bachelor's degree holders.

  4. Subgroup analysis of primary and secondary outcomes based on the baseline cognitive function

    Time frame: At 3 month and 12 month

    The investigators will perform a subgroup analysis for each outcome based on baseline cognitive function to determine whether the treatment effect varies according to baseline cognitive function. Participants with a baseline NIHTB-CB total composite T score ≤ 43 (corresponding to the lower 25th percentile adjusted for age, gender, education, and race/ethnicity) will be separately analyzed to those with a score > 43.

Study contacts

Contact information is provided by the study sponsor or research team.

Amelia Stocking

CONTACT

[email protected]

617-724-1976

Leonardo V. Riella, MD, PhD

CONTACT

[email protected]

6177240345 ext. 40345

Sponsors and collaborators

Lead sponsor

Massachusetts General Hospital

Other

Collaborators

  • Veloxis Pharmaceuticals

Registry information

Official study title

Neurocognitive Function Changes With Once-Daily Extended-Release Tacrolimus (Envarsus XR) Conversion Compared to Twice-Daily Immediate Release Tacrolimus Maintenance Among Older Kidney Transplant Recipients

Acronym: Neuro-KTR

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Dec 30, 2024
Registry last updated
May 28, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.